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Transcription factors PU.1 and CEBPA are required
for the proper coordination of enhancer activity dur-
ing granulocytic-monocytic (GM) lineage differentia-
tion to form myeloid cells. However, precisely how
these factors control the chronology of enhancer
establishment during differentiation is not known.
Through integrated analyses of enhancer dynamics,
transcription factor binding, and proximal gene
expression during successive stages of murine
GM-lineage differentiation, we unravel the distinct
kinetics by which PU.1 and CEBPA coordinate GM
enhancer activity. We find no evidence of a pioneer-
ing function of PU.1 during late GM-lineage differen-
tiation. Instead, we delineate a set of enhancers that
gain accessibility in a CEBPA-dependent manner,
suggesting a pioneering function of CEBPA. Ana-
lyses of Cebpa null bone marrow demonstrate that
CEBPA controls PU.1 levels and, unexpectedly,
that the loss of CEBPA results in an early differentia-
tion block. Taken together, our data provide insights
into how PU.1 and CEBPA functionally interact to
drive GM-lineage differentiation.
INTRODUCTION
Myeloid cells such as macrophages and neutrophilic granulo-
cytes constitute crucial components of the innate immune sys-
tem. According to the classical models for the hierarchical
architecture of the hematopoietic system, these cells develop
fromhematopoietic stemcells (HSCs) through a series of interme-
diate progenitor cells including common myeloid progenitors
(CMPs)—or their near equivalents, the pre-granulocytemonocyte
progenitors (preGMs)—and granulocytic-monocytic progenitors
(GMPs). Specifically, these progenitors have been found to expe-2744 Cell Reports 23, 2744–2757, May 29, 2018 ª 2018 The Author(s
This is an open access article under the CC BY license (http://creativerience increasing degrees of lineage restriction as they progress
along their path of differentiation (Orkin and Zon, 2008). The hier-
archical organization of the hematopoietic system has been
challenged by a number of studies that focus on single cells
demonstrating extensive heterogeneity in progenitor populations
previously thought to be homogeneous (Drissen et al., 2016; Paul
et al., 2015). As an example, immunophenotypically defined
CMPs harbor progenitors primed toward themegakaryocyte line-
age and themonocytic lineage, aswell as several granulocytic lin-
eages (Paul et al., 2015). This suggests that lineage priming is an
extensive phenomenon and that lineage fate decisions occur at
earlier differentiation stages than was previously thought.
The dynamic patterns of gene expression during hematopoiet-
ic differentiation are governed by interactions between transcrip-
tion factors (TFs) and proximal (promoter) and distal (enhancer)
cis-regulatory elements (Boyle et al., 2008; Heintzman et al.,
2009). Activities of distal enhancers are highly dynamic, as
exemplified by global analyses of enhancer dynamics during he-
matopoietic differentiation (Lara-Astiaso et al., 2014; Luyten
et al., 2014). More important, enhancer accessibility, as judged
by nucleosome-deficient regions or H3K4me1/me2 marking,
precedes gene expression.
PU.1 and CEBPA are key TFs during GM-lineage (myeloid) dif-
ferentiation (Rosenbauer and Tenen, 2007). PU.1 is expressed
throughout the hematopoietic hierarchy and is essential for the
formation of CMPs/preGMs (Iwasaki et al., 2005; Scott et al.,
1994). PU.1 binds to a vast number of enhancers and has been
suggested to act as a so-called pioneering factor at a subset
of these (Heinz et al., 2010). CEBPA is expressed during the latter
stages of GM differentiation and is indispensable for the forma-
tion of GMPs (Zhang et al., 2004). Similar to PU.1, a role for
CEBPA as a pioneering transcription factor has been suggested
based in part on its ability to enhance the formation of induced
pluripotent stem cells (iPSC) (Di Stefano et al., 2016; Ohlsson
et al., 2016). However, the extent to which CEBPA plays a similar
role during GM-lineage differentiation remains to be explored.
In line with their crucial importance during GM-lineage differ-
entiation, the expression of both Cebpa and Spi1 (encoding).
commons.org/licenses/by/4.0/).
CEBPA and PU.1, respectively) is tightly controlled. In humans,
14 different enhancers drive the expression ofCEBPA in different
tissues, with the 42 kb enhancer being responsible for the
CEBPA expression in the GM-lineage (Avellino et al., 2016).
Indeed, deletion of the corresponding and highly conserved
37 kb enhancer in the mouse efficiently ablates Cebpa expres-
sion in myeloid cells and leads to a phenotype that is essentially
indistinguishable from that of knocking out Cebpa in the entire
hematopoietic system (Avellino et al., 2016; Guo et al., 2016; Ha-
semann et al., 2014). Spi1 expression is to a large extent
controlled by a 14 kb enhancer, which in mice reduces the
levels of PU.1 by 80% upon deletion (Rosenbauer et al., 2004).
It is interesting that both PU.1 and CEBPA bind and activate
this enhancer, demonstrating both autoregulation and CEBPA-
dependent regulation of Spi1 expression (Yeamans et al.,
2007), although the importance of the latter has not been ad-
dressed in a proper in vivo setting.
Despite the evidence for extensive functional interplay be-
tween PU.1 and CEBPA, little is known of how these TFs work
together to control the chronology of enhancer establishment
during GM differentiation in a proper in vivo context. Here, we
use a genome-wide chromatin immunoprecipitation-sequencing
(ChIP-seq) approach to delineate the exact chronology of
enhancer establishment duringGMdifferentiation and its relation
with the activity of PU.1 and CEBPA. We show that PU.1 pre-
dominantly binds at enhancers established during the early
stages of differentiation and that late-established enhancers
are gradually less dependent upon PU.1 binding. We observed
instead that predominant CEBPA binding at late-established en-
hancers pointed toward a pioneering function of CEBPA at
these elements. The distinct kinetics in the binding profiles of
both PU.1 and CEBPA correlate with the enrichment of their
respective sequence-binding motifs at enhancers. Analysis of
Cebpa/ (knockout [KO]) cells revealed a marked reduction in
PU.1 binding at many enhancers, uncovering a surprising
CEBPA dependency for binding of PU.1. Finally, we used these
analyses to demonstrate that the loss of CEBPA leads to a GM
differentiation block preceding preGMs.
RESULTS
Enhancer and Gene Expression Dynamics during
GM-Lineage Differentiation
To characterize enhancer and gene expression dynamics
along the GM-lineage, we generated genome-wide H3K4me1
and H3K27ac profiles from sorted LSK (Lin, Sca-1+, ckit+),
preGM (constituting a subset of the CMPs; Lin, Sca-1, ckit+,
CD150, CD105), GMPs (Lin, Sca-1, ckit+, CD150,
FcgRII/III+), neutrophilic granulocytes (GRN), and monocytes
(MONO) representing five stages of murine GM differentiation
(Figures 1A and S1A–S1C; Table S1). Since the main function
of CEBPA is during granulocytic differentiation, we performed
our primary analysis on four populations (LSK, preGM, GMP,
and GRN). Additional analyses detailing the relative importance
of PU.1 and CEBPA during GRN/MONO lineage choice is
described in the latter part of this paper.
We used our recently developed peak-valley-peak (PVP)
method, which relies on the local H3K4me1 distribution for thedetection of active enhancers (Pundhir et al., 2016), to predict
a total of 44,002 enhancers across the four populations (Fig-
ure S2A; Table S2), most of which (86%) were located distally
(>500 bp) to transcription start sites (TSSs). Consistent with
our previous observations, our PVP-predicted enhancers only
displaymodest overlap (18%) with those derived from a classical
read density-based approach (Lara-Astiaso et al., 2014; Pundhir
et al., 2016). However, the PVP enhancers were associated with
higher levels of accessibility (H3K4me1 and assay for transpo-
sase-accessible chromatin using sequencing [ATAC-seq]) and
activity (H3K27ac), demonstrating that the H3K4me1 PVP
pattern is efficient in capturing active enhancers (Figure S3A).
Thus, our enhancer predictions provide an accurate map of the
regulatory complexity and dynamics during GM differentiation,
with enhancer regions showing distinct patterns of accessibility
(Figures 1B [early], 1C [throughout], and 1D [late]).
Globally, we observed two major groups of enhancers that
either maintain or lose H3K4me1 accessibility beyond the GMP
stage (GRN-active and GRN-inactive) (Figure 2A). Within each
group, we detected enhancer groups that gain and maintain
H3K4me1 accessibility across distinct GM-lineage stages.
These are exemplified by group 1 and group 5 enhancers, which
are established in LSKs, whereas group 3 and group 7 enhancers
are established at the GMP stage (Figure 2B). The accessibility
profile of enhancers from each group correlated with a gradual
gain in their activity as measured by H3K27ac levels and prox-
imal gene expression, both of which followed similar profiles
across the four stages (Figures 2C–2E and S3B).
Our enhancer classification was corroborated further by a
distinct enrichment profile of previously reported myeloid en-
hancers in the GRN-active group and of stem cell enhancers in
the GRN-inactive group (Lara-Astiaso et al., 2014) (Figure S3C).
This observation suggests an active role for GRN-active en-
hancers in GM-lineage differentiation and a role for GRN-inactive
enhancers during stem cell fate decisions. Indeed, we observed
an enrichment of myeloid, lymphoid, and erythroid enhancers in
the GRN-inactive group, consistent with the multipotent poten-
tial of LSK cells. However, we also note that even in this group,
the frequency of myeloid-specific enhancers supersedes that
of their lymphoid and erythroid counterparts, suggesting that
priming toward the myeloid lineage is a key feature of the most
immature blood cells. Finally, and consistent with their impor-
tance during myeloid differentiation, GRN-active enhancers are
enriched for H3K27ac when compared to their GRN-inactive
counterparts (Figures S2B–S2E). Taken together, we delineated
enhancers into distinct groups that exert their regulatory func-
tions across different stages of GM differentiation.PU.1 and CEBPA Bind to a Large Fraction of GM
Enhancers but Are Associated with Separate Groups of
Enhancer Accessibility
To determine the TFs that are potentially associated with
enhancer dynamics during GM differentiation, we compared
the enrichments of de novomotifs in GRN-active and GRN-inac-
tive enhancers. This demonstrates enrichment of the motifs that
are associated with the myeloid master regulator CEBPA in





































































































































































































































Figure 1. Experimental Outline
(A) Schematic diagram of the five GM differentiation stages profiled in the present study. Also shown are the datasets acquired from the different cell populations
(gray boxes).
(B–D) Examples of differential enhancer behavior illustrated by enhancers that become accessible early (B), accessible throughout (C), or accessible at late
differentiation stages (D). Shown are the normalized H3K4me1 andH3K27ac signal profiles (TPM) at these enhancers (gray boxes), as well as the gene expression
profiles of the nearest gene associated with these enhancers (boxes).
See also Figure S1.and GRN-active enhancers, which is consistent with the pan-he-
matopoietic importance of PU.1 (Figure S4A).
To elucidate further the roles of these factors during GM differ-
entiation, we performed ChIP-seq in LSKs, preGMs, and GMPs
and identified a total of 52,338 and 22,582 regions bound by
PU.1 and CEBPA, respectively (Figure S4). Whereas 49% of
PU.1-bound regionswere identified in all populations, the number
of CEBPA-bound regions increased gradually along the GM dif-
ferentiation path. These findings are consistent with the expres-
sion patterns for these factors because CEBPA is upregulated2746 Cell Reports 23, 2744–2757, May 29, 2018as cells progress from LSKs to GMPs, while PU.1 is highly ex-
pressed at all stages. Well-known binding motifs for PU.1 and
CEBPA were enriched in PU.1- and CEBPA-bound regions,
respectively, alongwithaprominentenrichmentof aPU.1-binding
motif inCEBPA-bound regions.Wefind31%ofCEBPA-bound re-
gions to be co-bound by PU.1 (Figure S4H) in GMPs, suggesting
an extensive degree of cooperation between PU.1 and CEBPA.
Next, we categorized our enhancer set into those bound by
either PU.1 or CEBPA, by both factors, or by others based on
TF-binding profiles in GMPs (see Experimental Procedures). A
Figure 2. Enhancer and Gene Expression Dynamics during GM-Lineage Differentiation
(A) Classification of 44,002 enhancers into two major groups based on their activity in granulocyte (GRN-active and GRN-inactive), and further subclassified into
four and three groups, respectively, based on their accessibility profile across the four GM-lineage differentiation stages (LSK, preGM, GMP, granulocytes). Filled
and unfilled circles represent accessible and non-accessible enhancers as determined by their H3K4me1-derived PVP patterns.
(B) Normalized H3K4me1 signal (TPM) at midpoint-centered enhancers (rows, ±1,000 bp) across the four GM-lineage differentiation stages (columns; both as
average and heatmap).
(C) The same as (B), but for H3K27ac.
(D) Scaled expression (Z score) of enhancer proximal genes across the four GM stages. Also shown is themedian scaled signal at each stage above the heatmap.
(E) Schematic illustration of the early to late establishment of enhancers from the seven groups.
See also Figures S2 and S3.substantial portion (36%) of these enhancers was bound by PU.1
and/or CEBPA and showed significantly higher levels of activity
(H3K27ac; highest for co-bound) than the levels displayed by en-
hancers devoid of the two TFs (Figures 3A–3C). We used these
data to determine the stages at which PU.1 and CEBPA exerted
their main functions during GM-lineage differentiation, focusingon the GRN-active enhancers. Here, we observed a striking cor-
relation between the timing of enhancer establishment and
PU.1-binding levels (i.e., enhancers that were established in
LSKs displayed higher levels of PU.1 in GMPs) (Figure 3E, group
1). Conversely, late-established enhancers displayed compa-
rably lower levels of PU.1 (groups 2 and 3). These observationsCell Reports 23, 2744–2757, May 29, 2018 2747
AB
E F G
C D Figure 3. Differential Behavior of PU.1 and
CEBPA at GM-Lineage Enhancers
(A) Enhancers (N = 44,002; bubbles) classified into
four categories on the basis of normalized PU.1
(y axis) and CEBPA (x axis) signals.
(B) Density plot of the H3K27ac signal at four
enhancer categories. ECDF, empirical cumulative
distribution function (Kolmogorov-Smirnov test).
(C) Differentially enriched de novo sequence motifs
at four enhancer categories. The top enriched and
depleted motifs are shown along with their best-
known motif match names.
(D) Fraction of enhancers from GRN-active groups
bound by PU.1, CEBPA, both PU.1 and CEBPA, or
other TFs (in GMPs).
(E) PU.1 binding signal (TPM) at enhancers
belonging to the four GRN-active groups from
LSKs to GMPs. p values (PU.1) represent the sig-
nificance level at which the PU.1 signal (preGM) at
enhancers from an earlier established group is
higher than at enhancers from a later-established
group (Wilcoxon rank-sum test).
(F) The same as (E), but for CEBPA binding.
p values (CEBPA) represent the significance level
at which CEBPA signal (GMP) at enhancers from
two adjacent groups are different.
(G) Differential enrichment of de novo sequence
motifs in the four GRN-active groups. The top en-
riched or depleted motifs are shown along with
their best-known motif match name.
See also Figure S4.correlated directly with the fraction of enhancers bound by PU.1
(Figure 3D). In contrast, CEBPA binding did not correlate with
early enhancer establishment but was instead found mainly on
group 3 enhancers that became established in GMPs (Figure 3F).
Again, a higher fraction of these enhancers was associated with
CEBPA binding compared to the other groups (Figure 3D). PU.1-
binding motifs were consistently mainly enriched in early estab-
lished enhancers, whereas CEBP motifs were preferably en-
riched in group 3 enhancers (Figure 3G).
Collectively, we have shown that PU.1 and CEBPA exert their
main effects on enhancers that are established in LSKs and
GMPs, respectively, and that the combined action of these two
factors controls the activities of a substantial proportion of
GM-lineage enhancers. Thus, our data uncover the underlying
molecular basis for the critical roles of PU.1 and CEBPA in the
formation of CMPs/preGMs and GMPs, respectively.
Loss of CEBPA Has a Strong Impact on PU.1 Binding
The current model of the PU.1/CEBPA interplay during late
stages of GM differentiation holds that PU.1 facilitates the bind-
ing of CEBPA to numerous genomic loci by acting as a pioneer-
ing factor (Heinz et al., 2010). This model is consistent with both
the expression patterns of PU.1 (early and maintained) and
CEBPA (induced late) during GM differentiation and the exten-
sive overlap of their binding profiles. However, given the early
differentiation block in Spi1/ myeloid progenitors, it has not
been possible to test this model in a proper in vivo context,2748 Cell Reports 23, 2744–2757, May 29, 2018and it remains a formal possibility that CEBPA also controls
PU.1 binding and levels.
Loss of CEBPA in murine bone marrow (BM) cells leads to a
differentiation block upstream of GMPs (Hasemann et al.,
2014; Zhang et al., 2004). To test the possibility that CEBPA
may affect PU.1 function or levels, we isolated preGMs from
Cebpa/ mice (preGM-KO) and generated genome-wide bind-
ing profiles for PU.1, H3K4me1, and H3K27ac. The loss of
CEBPA was associated with a significant loss of PU.1 peaks in
preGM-KO (30,893 versus 44,813 in preGM-wild-type [WT]),
suggesting that CEBPA controls the genome-wide association
of PU.1 (Figure 4A). Moreover, we observed an overall reduction
in PU.1 levels on the 44,002 GM-lineage enhancers when
comparing preGM-KO to their WT counterpart (Figure 4B).
Experiments in cell lines have shown that CEBPA binds and ac-
tivates the 14 kb Spi1 enhancer, which is a main driver of PU.1
transcription; this raises the possibility that the loss of CEBPA re-
duces the levels of PU.1 (Yeamans et al., 2007). We find that
CEBPA binds this enhancer in LSK cells and that the loss of
CEBPA is associated with a decrease in activity (H3K27ac; Fig-
ure 4C). We find reduced Spi1mRNA levels in preGM-KOs trans-
lating consistently into an approximate 2-fold reduction in PU.1
protein levels, as determined by quantitative mass spectrometry
comparisons ofWT and preGM-KOs (Figure 4D). Consistent with
a previous report, loss of CEBPA leads to upregulation of the
Cebpg mRNA and CEBPG protein (Figure 4D) (Alberich-Jorda`
et al., 2012). These findings clearly demonstrate that in addition
AD
B C
Figure 4. Loss of CEBPA Affects PU.1 Levels and Binding Properties
(A) Overlap between PU.1 peaks from WT and Cebpa KO preGMs.
(B) PU.1 density plots in WT and Cebpa KO preGMs (Kolmogorov-Smirnov test).
(C) University of California, Santa Cruz (UCSC) genome browser screenshot of PU.1 enhancers (gray). The 14 kb enhancer is indicated.
(D)Spi1 andCebpg expression (top) and corresponding protein levels (bottom) levels inWT andCebpaKO preGMs (gene expressionmeasured in DESeq2). Error
bars represent the SD between the three replicates.to the effect on CEBPA-bound enhancers, the loss of CEBPA
also affects enhancers bound by PU.1 because of the overall
reduction of PU.1 levels in preGM-KOs.
CEBPA Binds to GM-Lineage Enhancers in PU.1-
Dependent and -Independent Manners
Our analyses so far have demonstrated a complex interplay be-
tween PU.1 and CEBPA during GM differentiation. Because loss
of GMPs represents the main feature of CEBPA ablation, we
decided to focus on changes in enhancer accessibility during
the preGM to GMP transition.
To account for the recently reported heterogeneity in GMPs
(Olsson et al., 2016), we further fractionated this population
into colony-forming unit-granulocytes (CFU-Gs) and colony-
forming unit-macrophages (CFU-Ms) (primed toward GRN
and MONO production, respectively) and subjected these to
TFs and histone profiling (Figures S1C and S1D). Focusing
on GRN differentiation, we next ranked our 44,002 GM-lineage
enhancers (from Figure 2) on the basis of their changes in
H3K4me1 marks during the preGM to GMP transition. For
each of the resulting 13 subclusters, we assessed the levels
of PU.1, CEBPA, H3K4me1, H3K27ac, and gene expression
in LSKs, preGMs, preGM-KOs, GMPs, and CFU-Gs (Figures5A–5E). We further investigated the degree of change in
these features during the transition from LSK to preGM, from
preGM to GMP, and between WT and Cebpa/ preGM
(Figures 5F–5H). Enhancers belonging to cluster A gradually
lose H3K4me1 from LSKs to GMPs, correlating with a reduc-
tion in H3K27ac and gene expression. Only a minor fraction of
these enhancers is bound by PU.1 and/or CEBPA and mainly
constitute GRN-inactive enhancers enriched for stem cell and
non-GM-lineage enhancers (Figures 5I, 5J, and S3C). Cluster
B is constituted by enhancers that either maintain (Bi) or
moderately increase (Bii) their H3K4me1 levels as cells differ-
entiate from LSKs to GMPs. A quarter of these enhancers
(26%; 9,839 out of 37,519) are bound by PU.1 and this cluster
also is characterized by the highest fraction of PU.1/CEBPA
co-bound enhancers and by a transient gain of PU.1 binding
from LSK to preGM. Most subcluster Bi enhancers lose PU.1
binding when differentiating onward to GMPs, whereas the
Bii subcluster either maintains or further acquires PU.1 bind-
ing. Cluster B enhancers gain H3K27ac, but only the Bii sub-
cluster enhancers activate gene expression in GMPs. Sub-
cluster Bi enhancers overlap with stem and non-myeloid
GRN-inactive enhancers, likely containing enhancers that are
active in a variety of lineages (Figure 5J).Cell Reports 23, 2744–2757, May 29, 2018 2749
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Figure 5. PU.1 and CEBPA Binding Profiles during GM-Lineage Differentiation
The 44,002 GM enhancers were ranked (N = 13) based on the fold change in H3K4me1 signal between the GMP and preGM stages (GMP/preGM).
(A) Mean PU.1 signal at GM enhancers from each cluster.
(B–E) The same as (A), but for CEBPA (B), H3K4me1 (C), and H3K27ac (D) and for the expression of the nearest associated gene (E).
(F) Median fold change in PU.1, CEBPA, H3K4me1, and H3K27ac levels at enhancers from each cluster during the LSK to preGM transition along with gene
expression fold changes of the nearest associated gene.
(G and H) The same as (F), but for the preGM to GMP transition (G) and between WT and Cebpa KO preGMs (H).
(I) Fraction of enhancers bound by PU.1, CEBPA, both PU.1 and CEBPA, or other TFs.
(J) Differential enrichment of seven enhancer groups (from Figure 2) at enhancer clusters A, B, and C.
See also Figures S5 and S6.It is interesting that the transcription of cluster B enhancer-
driven genes is induced mainly transiently, suggesting that
they may be important for promoting preGM formation. Of
note, the gain of H3K27ac on subcluster Bii enhancers correlates
with CEBPA binding, suggesting that CEBPA activates en-
hancers already marked by PU.1. However, because these en-
hancers are bound by PU.1 already in LSKs, any potential
pioneering function of PU.1 will have to occur at earlier develop-
mental stages. Finally, cluster C contains enhancers that are es-
tablished mainly in GMPs. These enhancers are characterized
further by low levels of PU.1 in preGM and acquire CEBPA bind-
ing in GMPs, followed by an increase in PU.1 levels (Figures S5A
and S5B). This correlates strictly with the acquisition of H3K27ac2750 Cell Reports 23, 2744–2757, May 29, 2018and activation of gene expression. Indeed, cluster C enhancers
are highly enriched for CEBPA, suggesting that CEBPA is able
to assess closed chromatin in the absence of PU.1. The behavior
of clusters A–C enhancers are further stratified based on their
PU.1 and CEBPA binding status (Figure S6).
To gain further insight into the enhancers controlled by CEBPA
at the preGM to GMP transition we took advantage of our gene
expression data to define a group of CEBPA-dependent genes
(up during the preGMP to GMP transition and down in preGM-
KOs) and CEBPA-independent genes (down during the preGMP
to GMP transition and up in preGM-KOs compared to preGMs;
Figure S5C). CEBPA-dependent genes are markedly enriched
for genes involved in GM-specific gene programs and are
AB C D
E
Figure 6. Loss of CEBPA Leads to a Differ-
entiation Block Upstream of the preGM
(A) GSEA of preGMs derived from WT and Cebpa
KO BM.
(B) Principal component analysis (PCA) analysis of
H3K4me1 data on GM-lineage enhancers.
(C) The same as (B), but for PU.1 binding data.
(D) The same as (B), but for gene expression. Also
shown below each PCA plot is the correlation be-
tween signal values (H3K4me1, PU.1 or expres-
sion) in GMP and preGM WT or KO.
(E) Model illustrating the differentiation block in
Cebpa KO BM and its impact on Spi1 and Cebpg
expression. Loss of CEBPA will lead to increased
CEBPG levels, which in turn result in a lowering of
overall CEBP activity. We hypothesize that the
combined reduction in PU.1 and CEBPA activity is
responsible for the early differentiation block in
Cebpa KO BM.prominently controlled by cluster C enhancers (Figures S5D and
S5E). Conversely, CEBPA-independent genes are enriched for
T cell development pathways and are mainly controlled by clus-
ter A enhancers (Figures S5D and S5E). Finally, to directly
demonstrate a pioneering function of CEBPA during the preGM
to GMP transition, we re-expressed CEBPA in preGM-KO cells
to drive GM differentiation (Figures S5F–S5H). It is striking that
CEBPA binding to six of eight tested CEBPA-dependent en-
hancers (cluster C) was associated with a marked increase in
chromatin accessibility as detected by ATAC-qPCR (Figures
S5I and S5J). Conversely, a collection of six cluster A or B en-
hancers was unaffected by CEBPA expression. These results
demonstrate that CEBPA engages with closed chromatin and
facilitate the establishment of a class of signature GRN en-
hancers during the preGM to GMP transition.
Collectively, our analyses demonstrate that differentiation
along the GM path is associated with distinct patterns of
enhancer behavior involving (1) cluster A enhancers that shut
down mainly in a PU.1- and CEBPA-independent manner; (2)
the heterogeneous cluster B enhancers, which exhibit dynamic
patterns of PU.1 occupancy; and (3) the highly CEBPA-depen-Cell Rdent cluster C enhancers, which are acti-
vated at the GMP stage, in part through
the pioneering function of CEBPA, and
positively regulate the transcriptional pro-
gram required for GM differentiation.
CEBPA Loss Blocks GM
Differentiation Upstream of the
preGM Stage
Previous studies, including our own, have
demonstrated that Cebpa/mice exhibit
a differentiation block upstream of the
GMP (Hasemann et al., 2014; Mancini
et al., 2012; Zhang et al., 2004). The iden-
tity of the upstream progenitor depends
on the immunophenotyping strategies
used in these particular studies, andboth CMPs and preGMs have been shown to accumulate in
the absence of CEBPA. However, the immunophenotypes of
CMPs and preGMs only differ from the immunophenotype of up-
stream LSK cells by the loss of Sca-1 expression, thus rendering
the definition of these progenitors sensitive to the expression ki-
netics of thismarker. Moreover, because the functional definition
of Cebpa/ progenitors is prohibited by the inability of these
cells to sustain GM output, we decided to take a more global
approach to characterizing preGM-KO cells. The changes
across our ranked enhancers (clusters A–C) comparing KO to
WT preGMs were almost the complete opposite of the changes
occurring at the LSK to preGM transition (Figure 5H, compare to
Figure 5F), thereby placing immunophenically defined preGM-
KOs near the LSK compartment.
Gene set enrichment analysis (GSEA) demonstrated consis-
tently that preGM-KOs were enriched for the expression of a
pre-megakaryocyte erythrocyte progenitors (preMegEs) signa-
ture and depleted of the expression of a preGM signature relative
to their WT counterparts (Figure 6A). This, along with the
observed increased expression of a stem cell signature in
preGM-KOs, places this population upstream of its WTeports 23, 2744–2757, May 29, 2018 2751
counterpart (Figure 6A). Because our analysis of enhancer
usage demonstrates extensive dynamics of PU.1 binding and
H3K4me1 levels during differentiation along the GM-lineage,
we next used principal-component analysis of these features
as well as of global gene expression to further assign the differ-
entiation block of Cebpa/ GM progenitors. All three features
placed preGM-KOs upstream of preGM-WTs and immediately
downstream of LSKs (Figures 6B–6D). Overall, these findings
suggest that loss of CEBPA results in the inability of LSKs to
progress beyond the point of downregulation of Sca-1 expres-
sion, thereby moving the CEBPA restriction point to a position
well before the preGM population (Figure 6E).
The Distinct Chromatin Landscapes of Granulocytic and
Monocytic Progenitors Prime Their Differentiation
toward Mature Populations
CEBPA and PU.1 are known to drive differentiation toward the
granulocytic and monocytic lineages, respectively, but how
this differential behavior is coordinated and how it relates to
the recently described functional heterogeneity within the GMP
population remains unanswered. To address these questions,
we first classified 37,221 enhancers as common or specific to
GRN and MONO lineages based on the ratio of their H3K4me1
levels in granulocyte and monocyte populations, respectively
(Figure S7A; Experimental Procedures). Next, we assessed the
activity and TF occupancy at these enhancers in their corre-
sponding upstream progenitors. In support of a priming model,
we find that both GRN- and MONO-specific enhancers dis-
played higher levels of activity (H3K27ac) and proximal gene
expression already in their respective progenitor populations
(CFU-Gs and CFU-Ms) and that their activity gradually increased
as cells differentiate into granulocytes or monocytes (Figure 7A).
Furthermore, PU.1 binding was relatively higher at MONO-
compared to GRN-specific enhancers already in preGMs,
whereas a weak but opposite trend was observed for CEBPA
(Figure 7A). These findings are corroborated further by the
observed enrichment of CEBPA and PU.1 sequence motifs in
GRN- and MONO-specific enhancers, respectively (Figure 7D).
GRN-specific enhancers are highly enriched for the previously
defined CEBPA-dependent cluster C enhancers (Figure 7B).
Likewise, these enhancers are activated (H3K27ac) concomi-
tantly with the acquisition of CEBPA binding in CFU-Gs and
are associated with an increase in target gene expression (Fig-
ures 7A–7C). Although CEBPA binding to GRN-specific en-
hancers also increases in CFU-Ms, this increase is much less
pronounced and is not accompanied by increases in H3K27ac
and gene expression levels (Figure 7A).
For the MONO-specific enhancers, CEBPA binding remains
low while PU.1 occupancy increases, albeit to the same levels
in both CFU-Gs and CFU-Ms. The latter observation suggests
that other TFs are instrumental for monocyte differentiation in
line with the well-established role for interferon regulatory factor
(IRF) family members such as IRF8 (Figures 7A, S7B, and S7C)
(Becker et al., 2012). Indeed, several IRF motifs are selectively
enriched at MONO-specific enhancers, and IRF8 is the most
upregulated factor in CFU-Ms relative to CFU-Gs (Figures 7D
and 7E). Finally, a major fraction of enhancers (N = 22,332) was
common to both granulocytes andmonocytes. These enhancers2752 Cell Reports 23, 2744–2757, May 29, 2018displayed high levels of H3K27ac and gene expression in
preGM, which remained constant as the cells differentiated to-
ward CFU-Gs and CFU-Ms. While PU.1 occupancy at these en-
hancers decreased as preGMs differentiate into CFU-Gs or
CFU-Ms (Figure 7A), CEBPA binding increased, albeit more pro-
foundly in CFU-Gs (Figure 7A). The kinetics of PU.1 and CEBPA
are similar to our previous observation for PU.1-driven en-
hancers (cluster B in Figure 5) that govern the differentiation
from LSKs to preGMs. Indeed, we found a significant overlap be-
tween cluster B enhancers with this common group of GM en-
hancers (Figure 7B).
Finally, to discern the transcriptional program regulated by
GRN- and MONO-specific enhancers, we defined 376 (CFU-G)
and 457 (CFU-M) genes that are differentially expressed be-
tween the CFU-G and CFU-M populations (Figures 7E and
S7D). We observed an enrichment of functional categories that
are crucial for the immune function of each of the two lineages
(Figure S7E). We also detected a relative increase in the expres-
sion of cell-cycle genes in CFU-Ms compared to that of CFU-Gs
(Figures 7E and S7E). We hypothesize that the selective repres-
sion of cell-cycle genes in CFU-Gs is associated with the
increased expression of CEBPA in this compartment, which
would be consistent with its recognized function as a negative
regulator of proliferation (Johansen et al., 2001; Porse et al.,
2001).
In conclusion, MONO- and GRN-specific enhancers are estab-
lished as preGMs differentiate toward CFU-Ms and CFU-Gs,
respectively, and are differentially occupied by PU.1 and CEBPA
during GM-lineage differentiation (Figure 7F).
DISCUSSION
Defining how gene regulatory networks serve to shape biological
properties is key to understanding how cells progress from
immature stem and progenitor cells into their mature progeny.
Differentiation processes are governed by the actions of TFs,
some of which exhibit highly lineage-restricted expression pat-
terns. Within the hematopoietic system, CEBPA is expressed
almost exclusively in the GM branch of the hematopoietic hierar-
chy and is ultimately required for the development of mature
myeloid cells, but the underlying mechanisms for this require-
ment have remained elusive. By integrated analysis of enhancer
dynamics, TF binding, and proximal gene expression duringGM-
lineage differentiation in the context of a normal and a Cebpa/
hematopoietic system, we showed an extensive functional inter-
play between CEBPA and PU.1 in driving GM-lineage differenti-
ation. Moreover, our analyses also demonstrate that the loss of
CEBPA leads to a differentiation block at an earlier stage than
previously reported. Thus, our work yields insights into how
TFs functionally interact to drive differentiation along the GM-
lineage.
Enhancer Dynamics during Differentiation along the
GM-Lineage
Using our recently developed PVP approach for the analysis of
histone modifications, we defined the enhancer landscapes
during differentiation from multipotent progenitors (LSKs) to
mature neutrophilic granulocytes. A large fraction of identified
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Figure 7. Monocytic Enhancers Are Distinct from Granulocytic Enhancers in Terms of Their Transcription Factor Environment and Target
Genes
(A) Enhancers classified on the basis of their activity in granulocytic, monocytic, or both lineages. The dynamics of H3K4me1, H3K27ac, proximal gene
expression, PU.1, and CEBPA binding levels (quantile normalized) during differentiation of preGMs toward granulocytes or monocytes via the CFU-G or CFU-M
intermediates, respectively. Also shown is the fraction of enhancers from the three classes that are bound by PU.1, CEBPA, or both TFs in the GMP stage.
(B) Percentage of group C and B enhancers from Figure 5 that overlaps with common and granulocytic enhancers (Fisher’s exact test).
(C) A representative example of a CEBPA-bound enhancer active specifically in the granulocytic lineage.
(D) Differentially enriched sequence motifs in the three enhancer classes. The top enriched and depleted motifs are shown.
(E) Volcano plot for 833 differentially expressed (DE) genes between CFU-G and CFU-M. Names of selected DE genes are shown, along with the fraction of DE
cell-cycle genes between the two populations.
(F) Model illustrating the differential activity profile of PU.1 and CEBPA-dependent enhancers during GM differentiation. The CFU-GM population is indicated for
the sake of completion, although it was not assayed here.
See also Figure S7.enhancers was accessible already at the LSK stage and became
either more accessible (GRN-active) or was shut down (GRN-
inactive) during GM differentiation, demonstrating both a high
degree of enhancer dynamics and a high level of lineage priming
in immature populations (Lara-Astiaso et al., 2014; Paul et al.,2015). Indeed, enhancers that became closed in mature cells
were assigned mainly to non-GM-lineage genes and genes
associated with stem cell functions.
De novomotif analysis identified PU.1 and CEBPA as potential
key TFs at GRN-active enhancers. Consistent with this notion,Cell Reports 23, 2744–2757, May 29, 2018 2753
PU.1 and CEBPA bound pervasively to GM-lineage enhancers,
and enhancers bound by either or both of these factors were en-
riched for enhancer activity. PU.1 preferred enhancers that were
accessible at earlier stages, likely reflecting its role as a pan-he-
matopoietic master TF (Wilson et al., 2010). In contrast, CEBPA
bound mainly to late-accessible enhancers, which is consistent
with its expression pattern and its importance in inducing the
expression of genes involved in granulocyte function and devel-
opment. Finally, by additional subfractionation of GMPs into
CFU-Ms and CFU-Gs, we were able to provide evidence for
the selective importance of CEBPA in the latter population,
which is consistent with the view of CEBPA as the key TF during
granulocytic differentiation. Overall, these analyses reveal the
underlying molecular basis for the importance of both PU.1
and CEBPA in setting up gene regulatory programs during
GM-lineage differentiation.
Several Layers of Functional Interaction between PU.1
and CEBPA
PU.1hasbeen reported toserveasapioneering factor duringGM-
lineage differentiation, facilitating H3K4me1-driven enhancer for-
mation and subsequent recruitment of TFs, including CEBPs
(Heinz et al., 2010). Although these data clearly demonstrate the
ability of PU.1 to bind and remodel closed chromatin, the fact
that they were generated by re-expression of a PU.1-ER fusion
protein inaPU.1nullcontextdoesnotallowus toassess theextent
to which this occurs during normal GM-lineage differentiation. In
the present work, we observed little evidence for PU.1 binding to
closed chromatin,most likely reflecting the fact that a vast amount
of hematopoietic enhancers are marked by PU.1 already in HSCs
(Wilson et al., 2010). However, our data do not exclude a pioneer-
ing function for PU.1 at early stages suchasduringHSCspecifica-
tion or in other hematopoietic lineages.
Cluster C enhancers constitute a group of enhancers that re-
mains inaccessible in the absence of CEBPA. In contrast to
PU.1, CEBPA binding clearly correlates with the opening and
activation of these enhancers, and re-expression of CEBPA in
cultured Cebpa null progenitors was associated with enhancer
opening concomitant with CEBPA binding. These findings
strongly suggest that CEBPA acts as a pioneering factor on
selected enhancers, perhaps via its switch/sucrose non-
fermentable (SWI/SNF) domain, which has been shown to be
important for enhancer binding in adipocyte differentiation
(Madsen et al., 2014).
PU.1 and CEBPA exhibit extensive co-binding at GM-line-
age enhancers. A large degree of CEBPA binding occurs at
enhancers already bound by PU.1, but also we detect exam-
ples of enhancers in which PU.1 binding is dependent on
CEBPA. These examples include co-bound enhancers in
which PU.1 binding follows CEBPA occupancy (Figures 5,
S5A, and S5B). This dependency may reflect the lower
expression of PU.1 in Cebpa/ cells, where we observe an
overall reduction in PU.1 binding. The reduction in PU.1
expression could be traced back to the 14 kb Sfi1 enhancer,
where CEBPA binding was detected in LSK cells. Collectively,
our data suggest not only that CEBPA binds to chromatin in
PU.1-dependent and -independent manners but also that
CEBPA is important for maintaining appropriate levels of2754 Cell Reports 23, 2744–2757, May 29, 2018PU.1. Hence, these findings extend the current view on the
PU.1/CEBPA interplay during GM-lineage differentiation to-
ward a more active role for CEBPA.
Loss of CEBPA Leads to an Early Block in GM
Differentiation
Previous studies have placed the CEBPA-mediated differentia-
tion block during GM differentiation immediately upstream of
the GMP (Hasemann et al., 2014; Mancini et al., 2012; Zhang
et al., 2004). This was inferred from the accumulation of the imme-
diate upstream population (i.e., preGM or CMP), depending on
the specific immunophenotyping strategy. However, preGMs
and CMPs differ from the broad LSKpopulation only through their
lack of Sca-1 expression. Using gene expression data and
H3K4me1 and PU.1 ChIP-seq data, we showed that Cebpa/
preGMs mapped closely to LSKs, suggesting that the loss of
Cebpa leads to a differentiation block upstream of the preGM at
a stage immediately after downregulation of Sca-1 expression
(Figure 6E). Previous studies have shown that loss or functional
inactivation of CEBPA in various settings frequently is associated
with the aberrant expression of erythroid and lymphoid gene
expression signatures (Bereshchenko et al., 2009; Mancini
et al., 2012; Schuster et al., 2013; Wouters et al., 2007). Consis-
tently, preGM/CMP expressing no or functionally compromised
CEBPA shows an increased potential toward non-GM-lineages.
Moreover, in a leukemic setting, epigenetic silencing of CEBPA
sustains the production of leukemic blasts with both T cell and
GM characteristics, whereas BCR-ABL, normally associated
with GM leukemias, promotes the formation of erythroleukemias
when overexpressed in Cebpa/ progenitors (Figueroa et al.,
2009; Wagner et al., 2006; Wouters et al., 2007). Whereas these
non-GM-lineage characteristics of Cebpa/ progenitors have
been interpreted to reflect the loss of lineage fidelity imposed
by the absence ofCebpa, they may as well reflect a less differen-
tiated phenotype of Cebpa/ progenitors, which is consistent
with the model supported by our data. Indeed, this interpretation
is supported further by single-cell RNA sequencing (scRNA-seq)
analysis of Lin,Sca-1,c-kit+ progenitors, where loss of Cebpa
leads to the formation of a transcriptional cluster characterized
by the co-expression of GM, erythroid, and lymphoid genes
(Paul et al., 2015). We hypothesize that this cluster represents a
subset of our Cebpa/ preGMs.
Reports have highlighted the importance of CEBPA as a tran-
scriptional repressor in LSK cells, promoting the repression of
target genes such as Sox4 and Cebpg (Alberich-Jorda` et al.,
2012; Zhang et al., 2013). Consequently, the loss of CEBPA
leads to increased expression of these factors and the GMdiffer-
entiation block was rescued by short hairpin RNA (shRNA)-medi-
ated knock down of either of these factors. Whereas the under-
lying mechanism of SOX4 remains unclear, CEBPG, which lacks
a transactivation domain, was shown to control overall CEBP ac-
tivity in Cebpa/ progenitors through its ability to repress both
the levels and transactivation potential of CEBPB (Alberich-
Jorda` et al., 2012). The latter presumably occurs through the
leucine zipper-mediated heterodimerization with CEBPB, a fac-
tor that is able to functionally substitute for CEBPA, as evidenced
by the lack of any overt hematopoietic phenotypes of mice ex-
pressing Cebpb from the Cebpa locus (Jones et al., 2002).
Thus, the loss of CEBPA leads to an additional lowering of overall
CEBP activity below a threshold that is able to sustain GM-line-
age differentiation (Figure 6E).
Although the expression of single genes such as Cebpg may
explain the Cebpa/ phenotype, it is equally important to
consider the global impact of CEBPA during GM-lineage differ-
entiation. Differentiation from LSKs to preGM requires the coor-
dinated down- and upregulation (Figures S5C and S5D) of
numerous genes, and our enhancer analysis demonstrates that
a large proportion of these are bound by PU.1 and/or CEBPA
(Figure 5I). Given that PU.1 expression is lowered in Cebpa/
progenitors, presumably through the action of CEBPA on the
14 kb Sfi1 enhancer, and because PU.1 is bound to a vast
amount of GM enhancers, we consider it likely that the reduced
PU.1 level in the context of Cebpa/ progenitors is important at
the LSK to preGM transition. In support of this, the loss of PU.1
leads to the complete absence of CMPs, whereas heterozygous
animals exhibit a mild reduction in CMPs (Iwasaki et al., 2005). In
light of the extensive functional interplay between PU.1 and
CEBPA at GM enhancers, we hypothesize that the absence of
CEBPA, which is further exacerbated by the aforementioned
CEBPG-mediated lowering of CEBP activity, sensitizes LSK
cells to a reduction in PU.1 level, ultimately resulting in a differen-
tiation block upstream of the preGM (Figure 6E).
EXPERIMENTAL PROCEDURES
Mouse Work
Animals were housed according to institutional guidelines at the University
of Copenhagen. The conditional Cebpa null line and the Mx1Cre driver
lines were intercrossed to generate Cebpafl/fl and Cebpafl/fl;Mx1Cre and gen-
otyped as described previously (Hasemann et al., 2014; K€uhn et al., 1995; Lee
et al., 1997). Female mice 10–12 weeks old were subjected to three injections
(days 0, 2, and 4) with 200 mL polyinosinic-polycytidylic acid (pIpC; 1.5 mg/mL
in PBS; GE Healthcare) as described previously (Hasemann et al., 2014). Mice
were analyzed at day 18 after the first pIpC injection. Mouse work was per-
formed according to institutional guidelines and by permission of the Danish
Animal Experiments Inspectorate.
RNA-Seq
Total RNA was extracted from LSK, preGMs, GMP, CFU-G, CFU-M, granulo-
cytes, and monocytes in biological triplicates, using the RNeasy Micro Kit
(QIAGEN). RNA was processed for double-stranded cDNA synthesis using
the Ovation RNA-Seq System V2 (NuGEN). The sheared cDNA (fragment
size from 150 to 550 bp) was subjected subsequently to library preparation
using the Ovation Ultralow System V2 (NuGEN). The indexed cDNA libraries
were pooled in equimolar ratios and subjected to 75-cycles sequencing on
the NextSeq 500 System (Illumina).
ChIP-Seq
For histone marks and TF (PU.1 and CEBPA) we used 100,000-250,00 and
500,000 cells, respectively, per experiment. For neutrophils, we used
500,000–1,000,000 cells, given their availability. ChIP was performed as
described previously (Hasemann et al., 2014), except that cell lysates from
neutrophils were supplied with 5 nM NaF and 0.1 mM Na3VO4. The following
antibodies were used: PU.1 (Sc-352, Santa Cruz), CEBPA (14AA, Santa
Cruz), H3K4me1 (ab8895, Abcam), H3K27ac (ab4729, Abcam), and immuno-
globulin G (IgG) (Sc-2027, Santa Cruz). Washing procedures were optimized
for the individual antibodies as follows: PU.1: 2x rinse and 1x wash in radioim-
munoprecipitation assay (RIPA; 140 mM NaCl, 10 mM Tris-HCl, 1 mM
EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate, 1 mM
PMSF), followed by 4x wash in RIPA with 0.5 M NaCl, 1x wash in LiCl buffer
(250 mM LiCl, 10 mM Tris-HCl, 1 mM EDTA, 0.5% NP-40, and 0.1% sodiumdeoxycholate), and 2x wash in TE buffer (10 mM Tris-HCl, 1 mM EDTA).
H3K4me1/H3K27ac: 2x rinse in RIPA, followed by 4x wash in RIPA, 1x wash
in LiCl buffer, and 2x wash in TE buffer. CEBPA and IgG: As described by
Hasemann et al. (2014). Nucleotide sequences corresponding to the two rep-
licates from each cell population were mapped to mouse genome (mm9) using
Bowtie 2 (default parameters) (Langmead and Salzberg, 2012).
Prediction of Active Enhancer Regions
We used PARE (version 0.01), a computational method that captures
H3K4me1-defined open chromatin regions, to predict active enhancer regions
in the four GM differentiation stages (LSK, preGM, GMP, and granulocytes)
(Table S2) (Pundhir et al., 2016). We selected active enhancer regions that
were reproducible in both replicates at a false discovery rate (FDR) of <0.05.
This gave us a binary matrix of enhancer predictions (1: yes, 0: no) across
the four stages, which was used to define the enhancer groups (Supplemental
Experimental Procedures; Figure S2A). PU.1 and CEBPA signals were
measured at the predicted enhancer groups (Supplemental Experimental Pro-
cedures; Figure S4J). Enhancer predictions were benchmarked against pre-
dictions from Lara-Astiaso et al. (2014) for activity and chromatin accessibility
(see Supplemental Experimental Procedures for details).
Enrichment Analysis of Motifs
Motif enrichment was analyzed using HOMER (Heinz et al., 2010). Sequences
corresponding to enhancers or regions bound by TFs were retrieved. Enrich-
ment of TF-binding motifs, downloaded from MEME (Bailey et al., 2009),
was computed for sequences of interest and for an equal number of randomly
selected genomic fragments of the average region size, matched for guanine
and cytosine (GC) content and autonormalized to remove bias from lower-or-
der oligo sequences. Motif enrichment was calculated on repeat masked se-
quences using the cumulative binomial distribution. One hundred motifs
were searched for a range of motif lengths (7–14 bp), and after filtering for
redundant motifs, the top 50 motifs resulting from each search were com-
bined, leading to a final set of motifs. These were remapped and ranked ac-
cording to enrichment (depletion) in the enhancer groups.
Quantification and Statistical Analysis
ChIP-seq signals are normalized to tags permillion (TPM) and are shown as the
mean of the two replicates. Similarly, the mean of the three replicates of RNA-
seq experiments are reported for gene expression. The statistical tests used to
compute the significance level are mentioned along with the p values
throughout the text.
Data and Software Availability
The accession number for the ChIP-seq and RNA-seq data reported in this pa-
per is GEO: GSE89767.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.05.012.
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